OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
The webcast replay of the General Assembly Meeting of September 30, 2025 (in French), is available: click here
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.